Catalent, Inc. or Alkermes plc: Who Manages SG&A Costs Better?

Catalent, Inc. vs. Alkermes plc: A Decade of SG&A Management

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Catalent, Inc. and Alkermes plc have demonstrated distinct approaches to handling these costs. From 2014 to 2023, Catalent's SG&A expenses have shown a consistent upward trend, peaking at approximately 935 million in 2024, reflecting a 179% increase from 2014. In contrast, Alkermes plc has experienced a more moderate rise, with a 245% increase over the same period, reaching around 690 million in 2023. This data suggests that while both companies have increased their SG&A spending, Catalent's growth rate is more pronounced. However, the absence of data for Alkermes in 2024 leaves room for speculation on future trends. As the industry evolves, these insights provide a glimpse into the strategic financial management of two key players.